HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Core Viewpoint - HCW Biologics Inc. has announced a follow-on offering of 2,477,292 units at a price of $0.6055 per unit, aimed at funding clinical development and general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of units that include one share of common stock (or pre-funded warrant) and one warrant, each with an exercise price of $0.6055, exercisable upon shareholder approval [1]. - The gross proceeds from the offering are expected to be approximately $1.5 million before deducting fees and expenses [2]. - The closing of the offering is anticipated to occur on or about February 19, 2026, subject to customary closing conditions [1]. Group 2: Existing Warrants - The company has negotiated to reduce the exercise price of existing warrants from $2.41 to $0.6055 per share, pending shareholder approval [3]. Group 3: Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing immunotherapies targeting chronic inflammation and related diseases [6]. - The lead product candidate, HCW9302, is being evaluated in a Phase 1 clinical trial for autoimmune diseases [7]. - The company has developed over 50 molecules using its TRBC platform, which aims to create immunotherapeutics for various disease indications, including cancer and autoimmune diseases [6][7].